v3.25.1
Summary of Significant Accounting Policies - Schedule of Disaggregation of Total Product Sales (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Summary Of Significant Accounting Policies [Line Items]    
Total revenue $ 111,585 $ 69,222
Livmarli    
Summary Of Significant Accounting Policies [Line Items]    
Total revenue 73,224 42,845
Bile Acid Medicines    
Summary Of Significant Accounting Policies [Line Items]    
Total revenue 38,361 26,072
Total product sales, net    
Summary Of Significant Accounting Policies [Line Items]    
Total revenue 111,585 68,917
License and other revenue    
Summary Of Significant Accounting Policies [Line Items]    
Total revenue $ 0 $ 305